Zhou Yili, Chi Yili, Bhandari Adheesh, Xia Erjie, Thakur Prabhat Chandra, Qu Jinmiao, Wang Ouchen, Zhang Xiaohua
Department of Thyroid & Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang, PR China.
Nepal Cancer Hospital & Research Center Harisiddhi, Lalitpur, Nepal.
Am J Transl Res. 2020 Jun 15;12(6):3057-3067. eCollection 2020.
Placental-Cadherin (CDH3), a cell adhesion molecule, is associated with the function of cells to bind with other cells and the extracellular matrix (ECM). CDH3 is highly expressed in many malignancies, and has been proved it could be a serum marker to monitor colorectal cancer, but the CDH3 expression levels in thyroid cancer is still not clear. In this article, we will illuminate the correlation between CDHs expression and thyroid cancer.
We analyzed the level of CDH3 expression in 60 pair of tissue samples (contrast thyroid cancer tissues with adjacent normal thyroid tissues) by Real-time PCR, and TCGA data portal. After that, we transfected small interfering RNA to silence CDH3 in thyroid cancer cell lines (KTC-1 and BCPAP) and confirmed the function of CDH3 by performed colony formation, migration, invasion, cell counting kit-8 and apoptosis assays.
CDH3 was upregulated in thyroid cancer tissues compared to the adjacent normal tissues (T:N=71.87±39.88:5.35±5.91, P<0.0001) and TCGA (T:N=19.43±13.82:1.22±1.33, P<0.0001). In thyroid cell lines (KTC-1 and BCPAP) experiments showed that downregulated CDH3 inhibited proliferation, migration, and invasion. Meanwhile, inhibited CDH3 expression could upregulate E-cadherin, downregulated N-cadherin, which may control invasion and migration.
Thyroid cancer cells CDH3 expression levels is a correlation with its ability to grow, migrate and invade.
胎盘钙黏蛋白(CDH3)是一种细胞黏附分子,与细胞与其他细胞及细胞外基质(ECM)结合的功能相关。CDH3在许多恶性肿瘤中高表达,已被证明可作为监测结直肠癌的血清标志物,但CDH3在甲状腺癌中的表达水平仍不清楚。在本文中,我们将阐明钙黏蛋白(CDHs)表达与甲状腺癌之间的相关性。
我们通过实时荧光定量PCR和TCGA数据门户分析了60对组织样本(甲状腺癌组织与相邻正常甲状腺组织对比)中CDH3的表达水平。之后,我们转染小干扰RNA使甲状腺癌细胞系(KTC-1和BCPAP)中的CDH3沉默,并通过集落形成、迁移、侵袭、细胞计数试剂盒-8和凋亡检测来确认CDH3的功能。
与相邻正常组织相比,甲状腺癌组织中CDH3上调(T:N=71.87±39.88:5.35±5.91,P<0.0001),在TCGA数据中也是如此(T:N=19.43±13.82:1.22±1.33,P<0.0001)。在甲状腺细胞系(KTC-1和BCPAP)实验中表明,下调CDH3可抑制增殖、迁移和侵袭。同时,抑制CDH3表达可上调E-钙黏蛋白,下调N-钙黏蛋白,这可能控制侵袭和迁移。
甲状腺癌细胞中CDH3表达水平与其生长、迁移和侵袭能力相关。